BRPI0905369C8 - composição farmacêutica, uso da composição farmacêutica e kit compartimentado - Google Patents

composição farmacêutica, uso da composição farmacêutica e kit compartimentado

Info

Publication number
BRPI0905369C8
BRPI0905369C8 BRPI0905369A BRPI0905369A BRPI0905369C8 BR PI0905369 C8 BRPI0905369 C8 BR PI0905369C8 BR PI0905369 A BRPI0905369 A BR PI0905369A BR PI0905369 A BRPI0905369 A BR PI0905369A BR PI0905369 C8 BRPI0905369 C8 BR PI0905369C8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
compartmentalized kit
chronic
acute
osteoarticular
Prior art date
Application number
BRPI0905369A
Other languages
English (en)
Inventor
Vervaet Chris
Bastianelli Enrico
Attali Pierre
Original Assignee
Bone Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08101682A external-priority patent/EP2090307A1/en
Application filed by Bone Therapeutics filed Critical Bone Therapeutics
Publication of BRPI0905369A2 publication Critical patent/BRPI0905369A2/pt
Publication of BRPI0905369B1 publication Critical patent/BRPI0905369B1/pt
Publication of BRPI0905369B8 publication Critical patent/BRPI0905369B8/pt
Publication of BRPI0905369C1 publication Critical patent/BRPI0905369C1/pt
Publication of BRPI0905369C8 publication Critical patent/BRPI0905369C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
    • A61M5/281—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule
    • A61M5/283—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle using emptying means to expel or eject media, e.g. pistons, deformation of the ampoule, or telescoping of the ampoule by telescoping of ampoules or carpules with the syringe body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

composição farmacêutica, uso da composição farmacêutica e kit compartimentado. a presente invenção refere-se a uma composição farmacêutica intra-articular para utilização no tratamento e/ou prevenção de doenças osteoarticulares crônicas ou agudas e sintomas osteoarticulares crônicos ou agudos, principalmente, osteoartrite. esta composição inclui: possivelmente um veículo farmacêutico adequado ou diluente, um glicosaminoglicano, um componente activador do receptor adrenérgico alfa-2, um agente anti-inflamatório e células indiferenciadas.
BRPI0905369A 2008-02-15 2009-02-13 composição farmacêutica, uso da composição farmacêutica e kit compartimentado BRPI0905369C8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08101682A EP2090307A1 (en) 2008-02-15 2008-02-15 Pharmaceutical composition for the treatment or prevention of osteoarticular diseases
EP08101682.6 2008-02-15
EP08158285 2008-06-13
EP08158285.0 2008-06-13
PCT/EP2009/051739 WO2009101194A1 (en) 2008-02-15 2009-02-13 Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

Publications (5)

Publication Number Publication Date
BRPI0905369A2 BRPI0905369A2 (pt) 2015-06-30
BRPI0905369B1 BRPI0905369B1 (pt) 2019-04-24
BRPI0905369B8 BRPI0905369B8 (pt) 2020-02-04
BRPI0905369C1 BRPI0905369C1 (pt) 2020-11-17
BRPI0905369C8 true BRPI0905369C8 (pt) 2021-05-25

Family

ID=40550545

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0905369A BRPI0905369C8 (pt) 2008-02-15 2009-02-13 composição farmacêutica, uso da composição farmacêutica e kit compartimentado

Country Status (16)

Country Link
US (3) US20100285134A1 (pt)
EP (1) EP2252290B1 (pt)
JP (2) JP2011512345A (pt)
KR (2) KR101784642B1 (pt)
CN (1) CN101878029B (pt)
AU (1) AU2009214028B2 (pt)
BR (1) BRPI0905369C8 (pt)
CA (1) CA2703866C (pt)
DK (1) DK2252290T3 (pt)
ES (1) ES2658354T3 (pt)
HK (1) HK1149717A1 (pt)
IL (1) IL206080A (pt)
NO (1) NO2252290T3 (pt)
PL (1) PL2252290T3 (pt)
PT (1) PT2252290T (pt)
WO (1) WO2009101194A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100285134A1 (en) * 2008-02-15 2010-11-11 Bone Therepeutics Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases
US20120157391A1 (en) 2009-07-16 2012-06-21 Hirosaki University Proteoglycan-containing material
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN103429608B (zh) 2011-01-19 2016-08-03 国立大学法人弘前大学 蛋白多糖的大量制备方法
WO2013076162A1 (en) * 2011-11-21 2013-05-30 Université Libre de Bruxelles Formulations useful in the treatment of osteoarticular diseases
WO2013076160A1 (en) 2011-11-21 2013-05-30 Université Libre de Bruxelles Sustained release formulations useful in the treatment of diseases
ES2769850T3 (es) * 2012-07-25 2020-06-29 Univ Hirosaki Composición para prevenir o tratar la osteoartrosis
WO2016014408A1 (en) 2014-07-21 2016-01-28 Board Of Regents, The University Of Texas System Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
CN105232453B (zh) * 2015-10-30 2018-11-06 上海昊海生物科技股份有限公司 关节腔用地塞米松几丁糖纳米注射液及其制备方法
BR112019013503A2 (pt) 2016-12-31 2020-01-07 Bioxcel Therapeutics, Inc. Uso de dexmedetomidina sublingual para o tratamento da agitação
WO2019063320A1 (en) * 2017-09-27 2019-04-04 Universita' Degli Studi Di Padova COMPOSITION COMPRISING A BACTERICIDE / PERMEABILITY INCREASING PROTEIN AND HYALURONIC ACID FOR THE TREATMENT OF ARTHROPATHIES
IT201700108102A1 (it) * 2017-09-27 2019-03-27 Univ Degli Studi Padova Composizione di bactericidal/permeability increasing protein e acido ialuronico per il trattamento delle artropatie
CN112351809B (zh) 2018-06-26 2023-07-14 久光制药株式会社 微针装置及其制造方法
CN114983981A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
MX2022000709A (es) 2019-07-19 2022-05-19 Bioxcel Therapeutics Inc Regimenes de tratamiento con dexmedetomidina no sedante.
IT202200004574A1 (it) 2022-03-10 2023-09-10 Sergio Ammendola Nanoparticelle di N-acetilglucosammina e loro applicazioni
US11622949B1 (en) 2022-08-04 2023-04-11 Gad M. Gilad Agmatine compositions for treatment of osteoarthritis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906934A (en) * 1995-03-14 1999-05-25 Morphogen Pharmaceuticals, Inc. Mesenchymal stem cells for cartilage repair
US5869041A (en) * 1996-01-12 1999-02-09 The Miriam Hospital Delivery of bioactive compounds to an organism
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
BR9815499A (pt) * 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
CN1101405C (zh) * 1997-08-22 2003-02-12 电气化学工业株式会社 透明质酸凝胶的制备方法、用此方法制得的透明质酸及包含这种凝胶的医用材料
AU6056299A (en) 1998-09-21 2000-04-10 Musc Foundation For Research Development Non-hematopoietic cells, including cardiomyocytes and skeletal muscle cells, derived from hematopoietic stem cells and methods of making and using them
ATE489101T1 (de) 2000-04-25 2010-12-15 Osiris Therapeutics Inc Wiederherstellung der gelenken mit mesenchymalen stammzellen
WO2002005853A2 (en) * 2000-07-14 2002-01-24 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
DE10053053A1 (de) * 2000-10-19 2002-05-16 Knoell Hans Forschung Ev Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
JP2004535434A (ja) * 2001-06-25 2004-11-25 デピユイ 関節炎にかかった関節の処置のためのグリコサミノグリカン類のリポソームカプセル化
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US20070042951A1 (en) * 2003-10-08 2007-02-22 Allergan, Inc. Pharmaceutical compositions comprising alpha-2-adrenergics and trefoil factor family peptides
CN1890223A (zh) * 2003-10-31 2007-01-03 神经能质公司 辣椒素受体促效剂
US20060122150A1 (en) 2004-09-30 2006-06-08 Argentieri Dennis C Pharmaceutical composition and method for treating a joint-capsule arthropathy
EP1858502A1 (en) * 2005-03-04 2007-11-28 Acure Pharma AB Methods and pharmaceutical compositions for the treatment of neurological damage
NZ568694A (en) * 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
ITPD20060219A1 (it) * 2006-05-31 2007-12-01 Fidia Farmaceutici Composizioni farmaceutiche contenenti acido ialuronico solfatato nel trattamento dell'osteoartrosi
US20100285134A1 (en) * 2008-02-15 2010-11-11 Bone Therepeutics Pharmaceutical composition for use in the treatment and/or the prevention of osteoarticular diseases

Also Published As

Publication number Publication date
KR101784642B1 (ko) 2017-10-11
BRPI0905369B8 (pt) 2020-02-04
US20130084268A1 (en) 2013-04-04
CN101878029A (zh) 2010-11-03
IL206080A0 (en) 2010-11-30
JP6352995B2 (ja) 2018-07-04
WO2009101194A1 (en) 2009-08-20
KR20100134548A (ko) 2010-12-23
US20100285134A1 (en) 2010-11-11
JP2016196510A (ja) 2016-11-24
BRPI0905369B1 (pt) 2019-04-24
NO2252290T3 (pt) 2018-04-28
US20170056434A1 (en) 2017-03-02
ES2658354T3 (es) 2018-03-09
AU2009214028B2 (en) 2014-06-12
BRPI0905369A2 (pt) 2015-06-30
PT2252290T (pt) 2018-02-14
BRPI0905369C1 (pt) 2020-11-17
EP2252290A1 (en) 2010-11-24
AU2009214028A1 (en) 2009-08-20
CA2703866C (en) 2016-11-29
KR20160065988A (ko) 2016-06-09
HK1149717A1 (en) 2011-10-14
PL2252290T3 (pl) 2018-06-29
US9872876B2 (en) 2018-01-23
JP2011512345A (ja) 2011-04-21
DK2252290T3 (en) 2018-03-05
CN101878029B (zh) 2013-04-03
EP2252290B1 (en) 2017-11-29
IL206080A (en) 2016-11-30
CA2703866A1 (en) 2009-08-20
US9446065B2 (en) 2016-09-20
KR101669682B1 (ko) 2016-10-27

Similar Documents

Publication Publication Date Title
BRPI0905369C1 (pt) composição farmacêutica, composição e kit compartimentado
BRPI0622054B8 (pt) composto e composição farmacêutica
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
CL2008001633A1 (es) Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
EA201690904A1 (ru) Антибактериальная композиция для ротовой полости
CL2007001869A1 (es) Compuestos derivados de bencimidazol; procedimiento de preparacion; composiciones farmaceuticas; y uso para el tratamiento y/o profilaxis de enfermedades que se modulan con agonistas del fxr, tal como dislipidemias, diabetes, cancer, osteoporosis y e
EA200802184A1 (ru) Фармацевтические композиции с ингибиторами dpp iv
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112012006692A2 (pt) composição farmacêutica compreendendo ácido graxo de omega-3 e um derivado de hidróxi de uma estatina e métodos de uso das mesmas
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2012003026A1 (es) Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
CL2007003523A1 (es) Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
BRPI0914678A8 (pt) Dispositivo dispensador para vaso sanitário e processo para distribuir uma composição de tratamento a um dispositivo sanitário
SV2010003674A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
CL2007001648A1 (es) Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina.
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
BRPI0908124A2 (pt) Composto, ativador de glucoquinase, composição farmacêutica, uso de um composto ou sal farmacologicamente aceitavél do mesmo, e, métodos de ativação da glucoquinase, e para tratar e/ou prevenir uma doença
BRPI0713447A2 (pt) composição forma de dosagem oral sólida, e, método para o tratamento de dor
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
BR112012005044B8 (pt) composição farmacêutica que compreende uma combinação de (rac)-tramadol·hcl e celecoxib
BR112012022337A2 (pt) composição e respectivos método de preparação e uso de quantidade eficaz

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AOS INVENTORES.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 24/04/2020 QUANTO A DATA DE VALIDADE.

B25G Requested change of headquarter approved

Owner name: BONE THERAPEUTICS (BE)

B25A Requested transfer of rights approved

Owner name: BONE THERAPEUTICS (BE) ; GLOB-CO SRL (BE)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/02/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF